Verrica Pharmaceuticals Book Value Per Share Growth & History (VRCA)
Verrica Pharmaceuticals's book value per share was $1.44 for fiscal 2025.
View full Verrica Pharmaceuticals company overviewVerrica Pharmaceuticals annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.44 | $2.51 | — |
| 2024 | 2024-12-31 | -$1.07 | -$5.73 | — |
| 2023 | 2023-12-31 | $4.66 | -$5.08 | −52.17% |
| 2022 | 2022-12-31 | $9.74 | -$2.11 | −17.78% |
| 2021 | 2021-12-31 | $11.85 | -$1.12 | −8.62% |
| 2020 | 2020-12-31 | $12.97 | -$12.25 | −48.58% |
| 2019 | 2019-12-31 | $25.21 | -$9.58 | −27.53% |
| 2018 | 2018-12-31 | $34.79 | $53.82 | — |
| 2017 | 2017-12-31 | -$19.03 | — | — |
Verrica Pharmaceuticals quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.25 | $2.14 | — |
| Q1 2026 | 2026-03-31 | $0.93 | $2.96 | — |
| Q4 2025 | 2025-12-31 | $1.44 | $2.51 | — |
| Q3 2025 | 2025-09-30 | -$1.80 | $5.67 | — |
| Q2 2025 | 2025-06-30 | -$1.89 | $1.24 | — |
| Q1 2025 | 2025-03-31 | -$2.02 | -$2.38 | — |
| Q4 2024 | 2024-12-31 | -$1.07 | -$5.73 | — |
| Q3 2024 | 2024-09-30 | -$7.47 | -$17.52 | — |
| Q2 2024 | 2024-06-30 | -$3.13 | -$16.37 | — |
| Q1 2024 | 2024-03-31 | $0.36 | -$15.14 | −97.71% |
| Q4 2023 | 2023-12-31 | $4.66 | -$5.08 | −52.17% |
| Q3 2023 | 2023-09-30 | $10.06 | -$0.84 | −7.68% |
| Q2 2023 | 2023-06-30 | $13.24 | $7.32 | +123.88% |
| Q1 2023 | 2023-03-31 | $15.49 | $6.29 | +68.39% |
| Q4 2022 | 2022-12-31 | $9.74 | -$2.11 | −17.78% |
| Q3 2022 | 2022-09-30 | $10.89 | -$3.95 | −26.62% |
| Q2 2022 | 2022-06-30 | $5.91 | -$13.04 | −68.81% |
| Q1 2022 | 2022-03-31 | $9.20 | -$13.28 | −59.08% |
| Q4 2021 | 2021-12-31 | $11.85 | -$1.12 | −8.62% |
| Q3 2021 | 2021-09-30 | $14.84 | -$0.30 | −2.00% |
| Q2 2021 | 2021-06-30 | $18.96 | $0.18 | +0.97% |
| Q1 2021 | 2021-03-31 | $22.48 | $0.56 | +2.53% |
| Q4 2020 | 2020-12-31 | $12.97 | -$12.25 | −48.58% |
| Q3 2020 | 2020-09-30 | $15.15 | -$12.68 | −45.57% |
| Q2 2020 | 2020-06-30 | $18.77 | -$11.08 | −37.12% |
| Q1 2020 | 2020-03-31 | $21.93 | -$10.26 | −31.88% |
| Q4 2019 | 2019-12-31 | $25.21 | -$9.58 | −27.53% |
| Q3 2019 | 2019-09-30 | $27.83 | -$9.67 | −25.78% |
| Q2 2019 | 2019-06-30 | $29.85 | -$9.68 | −24.49% |
| Q1 2019 | 2019-03-31 | $32.19 | — | — |
| Q4 2018 | 2018-12-31 | $34.79 | $53.82 | — |
| Q3 2018 | 2018-09-30 | $37.50 | — | — |
| Q2 2018 | 2018-06-30 | $39.54 | — | — |
| Q4 2017 | 2017-12-31 | -$19.03 | — | — |
Verrica Pharmaceuticals book value per share trends
Over the last five fiscal years, Verrica Pharmaceuticals's book value per share decreased from $12.97 to $1.44, a change of -$11.53. The latest reported quarter, Q2 2026, shows $0.25.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Verrica Pharmaceuticals source filings ↗